AzTrials
AzTrials

InsomniaPhase 3NCT00856973

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

A Phase 3 study testing eszopiclone in people with Insomnia and Attention Deficit Hyperactivity Disorder, run by Sumitomo Pharma America, Inc. at 73 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia. Read more about this study

Who is it for?
Ages 6 to 17 years
What is being tested?
eszopiclone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
486 participants
Where
73 sitesUnited States
Study dates
May 2009to Jul 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Subject is male or female 6 to 17 years of age, inclusive, at the time of consent.
  • Subject must have a diagnosis of ADHD as defined by DSM-IV criteria
  • Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation, (wake time after sleep onset >45 minutes) despite adequate age appropriate time and opportunity for sleep.
  • Subject's Baseline PSG must reveal either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake after sleep onset (WASO).
  • Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.
  • Subject or subject's parent/legal guardian should have reported attempted and failed behavioral interventions for sleep problems, including a regular bedtime and rise time
Show all 10Show fewer
  • Subject's sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication whether it is being used as intended or in an illicit manner.(Female subjects ≥8 years of age must have a negative serum pregnancy test)
  • Subject must be in general good health
  • Subject must be able to swallow tablets.
  • If subject is currently taking medication for ADHD, they must be on a stable dose and regimen for a minimum of 1 month prior to the time of consent

Who cannot join

  • Subject with weight <10th percentile for age and gender
  • Subject has any clinically significant or unstable medical illness/abnormality or chronic disease.
  • Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder or any history of psychosis.
  • Subject has periodic limb movement >5 times per hour, as demonstrated on Baseline PSG.
  • Subject has sleep disordered breathing, as demonstrated on Baseline PSG.
  • Subject has another primary sleep disorder, a secondary sleep disorder, or any other known or suspected medical or psychiatric condition that has affected or may affect sleep
Show all 14Show fewer
  • Subject has a history of circadian rhythm disorder or will travel across ≥3 time zones more than once during the study.
  • Subject has organic brain disease, or a history of febrile seizures.
  • Subject is, in the opinion of the investigator, at suicidal or homicidal risk.
  • Female subject who is pregnant or lactating or planning to become pregnant.
  • Subject has taken any psychotropic medication without an appropriate washout period (≥5 half-lives) prior to randomization.
  • Subject has a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.
  • Subject has a history of allergic reaction or has a known or suspected sensitivity to racemic zopiclone, eszopiclone, or any substance that is contained in the formulation.
  • Subject has a history of alcohol or substance abuse within 3 months of study participation.

Trial locations and contacts

73 sites in 1 country.

73 sites in 1 country

United States73 sites
  • Neuro Trials Research, Inc.

    Atlanta, Georgia, 30342

  • Sleep Disorders Center of Georgia

    Atlanta, Georgia, 30342

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007

  • Sleep Disorders Center of Alabama

    Birmingham, Alabama, 35213

  • Neurobehavioral Medicine Group

    Bloomfield Hills, Michigan, 48302

  • AV Institute, Inc.

    Carson, California, 90746

  • Metropolitan Neuro Behavioral Institute

    Chandler, Arizona, 85226

  • Carolina Clinical Trials Inc.

    Charleston, South Carolina, 29405

  • Tristate Sleep Disorders Center

    Cincinnati, Ohio, 45246

  • Delta Waves, INC

    Colorado Springs, Colorado, 80918

  • Clinical Innovations, Inc.

    Costa Mesa, California, 92626

  • InSite Clinical Research LLC

    DeSoto, Texas, 75115

  • Dothan Behavioral Medicine Clinic

    Dothan, Alabama, 36303

  • Mountain West Clinical Trials

    Eagle, Idaho, 83616

  • Synergy Clinical Research Center

    Farmingdale, New York, 11735

  • Avastra Clinical Trials

    Fountain Valley, California, 92708

  • Sarkis Clinical Trials

    Gainesville, Florida, 32607

  • MD & Associates, Inc.

    Garfield Heights, Ohio, 44125

  • Clinical Insights

    Glen Burnie, Maryland, 21061

  • Behavioral Research Specialists, LLC

    Glendale, California, 91204

  • Mid-Michigan Sleep Center

    Grand Blanc, Michigan, 48439

  • Cyn3rgy Research

    Gresham, Oregon, 97030

  • MD Clinical

    Hallandale, Florida, 33009

  • Clinical Research Center of Nevada

    Henderson, Nevada, 89015

  • Alexian Brothers Center for Psychiatric Research

    Hoffman Estates, Illinois, 60169

  • Claghorn-Lesem Research Clinic

    Houston, Texas, 77008

  • Allegiant Clinical Research, LLC

    Houston, Texas, 77024

  • MD

    Houston, Texas, 77042

  • Todd J. Swick, MD, PA

    Houston, Texas, 77063

  • Davis Clinic

    Indianapolis, Indiana, 46260

  • Goldpoint Clinical Research

    Indianapolis, Indiana, 46260

  • Eastside Therapeutic Resource

    Kirkland, Washington, 98033

  • Center for Psychiatry and Behavioral Medicine, Inc.

    Las Vegas, Nevada, 89128

  • Premier Psychiatric Research Institute, LLC

    Lincoln, Nebraska, 68510

  • Paul E. Wylie

    Little Rock, Arkansas, 72211

  • Pacific Institute for Medical Research Inc

    Los Angeles, California, 90024

  • MD

    Lubbock, Texas, 79423

  • Florida Clinical Research Center LLC

    Maitland, Florida, 32751

  • AMR Baber Research Inc.

    Naperville, Illinois, 60563

  • Louisiana Research Associates, Inc.

    New Orleans, Louisiana, 70114

  • Neurocare, Inc.

    Newton, Massachusetts, 02459

  • American Medical Research, Inc.

    Oak Brook, Illinois, 60523

  • Excell Research, Inc.

    Oceanside, California, 92056

  • North County Clinical Research (NCCR)

    Oceanside, California, 92056

  • IPS Reserach Company

    Oklahoma City, Oklahoma, 73103

  • Pahl Pharmaceutical Professionals, LLC

    Oklahoma City, Oklahoma, 73112

  • Cutting Edge Research Group

    Oklahoma City, Oklahoma, 73116

  • Eminence Research, LLC

    Oklahoma City, Oklahoma, 73139

  • Pacific Clinical Research Medical Group

    Orange, California, 92868

  • SDS Clinical Trials

    Orange, California, 92868

  • Aspen Clinical Research, LLC

    Orem, Utah, 84058

  • Florida Institute for Clinical Research, LLC

    Orlando, Florida, 32822

  • Psychiatric Associates

    Overland Park, Kansas, 66211

  • Pedia Research LLC

    Owensboro, Kentucky, 42301

  • California Clinical Trials Medical Group

    Paramount, California, 90723

  • CRI Worldwide

    Philadelphia, Pennsylvania, 19139

  • PsyPharma Clinical Research

    Phoenix, Arizona, 85050

  • The Mech Center

    Plano, Texas, 75024

  • Oregon Center for Clinical Investigations, Inc.

    Portland, Oregon, 97210

  • Clinical Innovations, Inc.

    Riverside, California, 92506

  • Midwest Research Group

    Saint Charles, Missouri, 63301

  • Artemis Institute for Clinical Research

    San Diego, California, 92123

  • Clinical Innovations, Inc.

    San Diego, California, 92128

  • Neuropsychiatric Research Center of Orange County

    Santa Ana, California, 92701

  • Clinical Innovations, Inc.

    Santa Ana, California, 92705

  • SomnoMedics, LLC

    Tampa, Florida, 33607

  • Pediatric Epilepsy and Neurology Specialists

    Tampa, Florida, 33609

  • Clinical Neurophysiology Services, P.C.

    Troy, Michigan, 48085

  • REM Medical Clinical Research

    Tucson, Arizona, 85712

  • Tulsa Clinical Research

    Tulsa, Oklahoma, 74104

  • Paradigm Research Professional, LLP

    Tulsa, Oklahoma, 74114

  • Elite Clinical Trials

    Wildomar, California, 92595

  • CRI Worldwide, LLC

    Willingboro, New Jersey, 08046

Other trials in United States

About this study

Official title: A Randomized, Placebo Controlled, Double Blind, Fixed Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia

A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.

Read the detailed description

This is a multi center, randomized, double blind, placebo controlled, fixed dose study of eszopiclone in pediatric subjects 6-17 years of age, inclusive, with ADHD associated insomnia. Subjects will be randomized at approximately 1:1:1 to either low dose oral eszopiclone (1 mg for children ages 6-11 years, 2 mg for adolescents ages 12-17 years), high dose oral eszopiclone (2 mg for children ages 6-11 years, 3 mg for adolescents ages 12-17 years) or placebo. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Being tested
eszopiclone, Placebo
Keywords
Hypnotic, Eszopiclone, Attention Deficit/Hyperactivity Disorder, Insomnia, Children, Adolescent, Polysomnography, Actigraphy
Medical subject headings
Sleep Initiation and Maintenance Disorders, Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • eszopicloneDrug

    1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years

  • eszopicloneDrug

    2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years

  • PlaceboDrug

    1 tablet per day for 12 weeks

Study groups in NCT00856973
Study groupRoleWhat they receive
Low dose eszopicloneExperimental1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
Receives: Drug: eszopiclone
High dose eszopicloneExperimental2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
Receives: Drug: eszopiclone
PlaceboPlacebo comparatorPlacebo 6-17 years
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS).

    A central scoring facility was used to derive the PSG sleep parameters Latency to Persistent Sleep (LPS) from the epochs and stages collected via the PSG recordings. Each epoch is 30 seconds. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Change from BL at Week 12 in LPS was derived from Week 12 LPS subtracted by BL LPS. Latency to persistent sleep (LPS; minutes): time from lights out to the first of 20 consecutive epochs (10 minutes) of non-wake, as determined by PSG recordings.

    Measured: Baseline (Day 0) to Week 12

Secondary outcomes (19)
  1. Change From Baseline (Day 0) to Week 12 in PSG Defined Wake Time After Sleep Onset (WASO)

    A central scoring facility was used to derive the PSG sleep parameters Wake Time After Sleep Onset (WASO) from the epochs and stages collected via the PSG recordings. Each epoch is 30 seconds. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Change from BL at Week 12 in WASO was derived from Week 12 WASO subtracted by BL WASO. Wake time after sleep onset (WASO; minutes): The number of wake epochs after the onset of persistent sleep to the end of the recording, divided by 2.

    Measured: Baseline (Day 0) to Week 12

  2. Change From Baseline in Clinical Global Improvement (CGI)-Parent/Caregiver at Week 12

    The CGI-I Parent/Caregiver was completed by the investigator based on interviews and interactions with the subject's parent or caregiver and represented their assessment of severity and improvement in the subject's symptoms since the start of the study. A 7 point scale was used for improvement with numeric values assigned to each of the responses: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), and very much worse (7).

    Measured: Baseline (Day 0) to Week 12

  3. Change From Baseline in CGI-Child at Week 12

    The CGI - I Child was completed by the investigator based on interviews and interactions with the subject and represented the subject's assessment of improvement in his/her symptoms since the start of the study. A 7 point scale was used for improvement with numeric values assigned to each of the responses: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), and very much worse (7).

    Measured: Baseline (Day 0) to Week 12

  4. Change From Baseline (Day 0) to Week 12 in Conners' ADHD Inattention Rating Scale.

    The Conners' 3 -Parent Short Form was completed by the parent and provided an assessment of Attention-Deficit/ Hyperactivity Disorder (ADHD) and the most common comorbid problems and disorders in children and adolescents. It is a multi-informant assessment of children and adolescents between 6 and 18 years of age that took into account home, social and school settings. The short version of the Conners' 3 -Parent Short Form was a subset of items from the full-length form, and included the Conners' 3 Content Scales of Inattention, Hyperactivity/Impulsivity, Learning Problems, Executive Functioning, Aggression, and Peer/Family Relations. The scale scores were presented as standardized age and gender based t scores. Inattention score was used for this endpoint. The lowest scale score is 40 (best) and the highest is 90 (worse)].

    Measured: Baseline (Day 0) to Week 12

  5. Change From Baseline to Week 12 in Subjective SL (Sleep Latency)

    A Sponsor produced sleep questionnaire asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of SL over a pre-defined time period. SL is subjective time to fall asleep.

    Measured: Baseline (Day 0) to Week 12

  6. Change From Baseline to Week 12 in Subjective Wake Time After Sleep Onset (WASO).

    A Sponsor produced sleep questionnaire asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of WASO over a pre-defined time period. WASO is the aggregate duration of awakenings from the time subjects fall asleep until last awakening. Wake time after sleep onset (WASO; minutes): The number of wake epochs after the onset of persistent sleep to the end of the recording, divided by 2.

    Measured: Baseline (Day 0) to Week 12

  7. Change From Baseline to Week 12 in PSG Defined Sleep Efficiency (SE)

    A central scoring facility was used to derive the PSG sleep parameter of Sleep Efficiency (SE) from the epochs and stages collected via the PSG recordings. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Sleep efficiency: (total sleep time)/(total recording time) x 100. For this endpoint, total sleep time was defined as the number of non-wake epochs from the beginning of recording to the end of recording divided by 2. If total recording time was greater than 960 epochs (480 minutes), total sleep time was calculated from the PSG truncated at 480 minutes.

    Measured: Baseline (Day 0) to Week 12

  8. Change From Baseline to Week 12 in PSG Defined Number of Awakenings After Sleep Onset (NAASO).

    A central scoring facility was used to derive the PSG sleep parameter of Number of Awakenings after Sleep Onset (NAASO). The PSG parameters provided an objective assessment of the subject's sleep on a given night. Number of awakenings: The number of times, after onset of persistent sleep, that there was a wake entry of at least one-minute duration. Each awakening must have been separated by an epoch of non rapid eye movement (NREM) sleep stage 2, 3/4, or rapid eye movement (REM) sleep.

    Measured: Baseline (Day 0) to Week 12

  9. Change From Baseline to Week 12 in PSG Defined Total Sleep Time (TST)

    A central scoring facility was used to derive the PSG sleep parameter of Total Sleep Time (TST) from the epochs and stages collected via the PSG recordings. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Total sleep time was defined as the number of non-wake epochs from the beginning of recording to the end of recording divided by 2. If total recording time was greater than 960 epochs (480 minutes), total sleep time was calculated from the PSG truncated at 480 minutes.

    Measured: Baseline (Day 0) to Week 12

  10. Change From Baseline to Week 12 in Subjective Total Sleep Time (TST).

    A Sponsor produced sleep questionnaire asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of TST over a pre-defined time period. TST is subjective total sleep time.

    Measured: Baseline (Day 0) to Week 12

  11. Change From Baseline to Week 11 in Subjective Sleep Latency (SL) Measured by Actigraphy Monitoring in the Actigraphy Population.

    A central scoring facility was used to derive the actigraphy sleep parameter of Sleep Latency (SL). Actigraphy data were used for additional efficacy evaluation as well as for the evaluation of rebound and withdrawal effects.

    Measured: Baseline (Day 0) to Week 11

  12. Change From Baseline to Week 11 in Subjective WASO From Actigraphy Population.

    A central scoring facility was used to derive the actigraphy sleep parameters Wake Time After Sleep Onset (WASO). Actigraphy data were used for additional efficacy evaluation as well as for the evaluation of rebound and withdrawal effects.

    Measured: Baseline (Day 0) to Week 11

  13. Change From Baseline to Week 11 in Total Sleep Time (TST) Measured by Actigraphy Monitoring in the Actigraphy Population.

    A central scoring facility was used to derive the actigraphy sleep parameter of Total Sleep Time (TST). Actigraphy data were used for additional efficacy evaluation as well as for the evaluation of rebound and withdrawal effects.

    Measured: Baseline (Day 0) to Week 11

  14. Change From Baseline to Week 12 in Pediatric Daytime Sleepiness Scale (PDSS) Total Score.

    The PDSS is a validated measure of excessive sleepiness specifically designed for use in school aged children. The scale allowed for measurement of sleepiness across several relatively sedentary activities and provided a means to unmask sleepiness that may not be recognized during more active situations. It consisted of 8 items that assessed the frequency of a sleep related behavior (eg, how often do you fall asleep or get drowsy during class periods; are you usually alert most of the day; how often do you think you need more sleep) using a 5-point Likert type scale (0 = never, 4 = always). All items were summed to obtain the PDSS total score. PDSS data were used for efficacy evaluation as well as for the evaluation of residual effects.The overall PDSS scores range from a low of 0 where the individual is endorsing each item at the lowest level of sleepiness to a high of 32 where the individual is endorsing each item at the highest level of sleepiness.

    Measured: Baseline (Day 0) to Week 12

  15. Change From Baseline to Week 12 in Coding Copy Subtest / Digit Symbol Substitution Test (DSST) Scaled Score.

    These tests are standardized information processing tasks to assess recognition and recoding of sensory information. The subject was given 90 seconds to complete as many substitutions of symbols as possible according to a code provided on top of the sheet. The Coding Copy Subtest A was used for subjects 6-7 years of age and the Coding Copy Subtest B was used for subjects 8-16 years of age, and the DSST was used for subjects 17 years of age. The score is the number of squares filled in correctly. Individuals are measured against their own pre-treatment baseline to determine levels of impairment using the scaled score. Higher scores mean less impairment (or potentially improvement) as the number of correct substitutions generally improves as cognition improves. Scaled scores are used to account for age differences among test takers. Scaled scores range from 1 to 19, and higher scores indicate higher cognitive function.

    Measured: Baseline (Day 0) to Week 12

  16. Change From Baseline to Week 12 in Pediatric Quality-of-Life Scale (Short Form-10).

    The SF 10 Health Survey for Children is a 10 item care-giver completed assessment designed to measure children's health-related quality of life. The scale asked questions about the child's physical wellness, feelings, behavior, and activities at school and with family and friends. The SF 10 Physical and Psychosocial summary measures were scored such that higher scores indicated more favorable functioning.

    Measured: Baseline (Day 0) to Week 12

  17. Change From Baseline to Week 12 in Subjective Number of Awakenings After Sleep Onset (NAASO).

    A Sponsor produced sleep questionnaire asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of NAASO over a pre-defined time period.

    Measured: Baseline (Day 0) to Week 12

  18. Change in School Tardiness/Attendance Reports at Week 12 (Days)

    School tardiness/attendance reports were to be collected when subject was actively enrolled in school (fall and spring semesters only; summer school, camps or other school attendance was not recorded.) The School Tardiness Report captured the number of days that the subject was tardy to school, had partial attendance at school or was completely absent from school. Data were collected for the 30-day period prior to Baseline, 6-week period prior to Week 6, 6-week period prior to Week 12.

    Measured: Baseline (Day 0) to Week 12

  19. Change in School Tardiness/Attendance Reports at Week 12 (Hours)

    School tardiness/attendance reports were to be collected when subject was actively enrolled in school (fall and spring semesters only; summer school, camps or other school attendance was not recorded.) The School Tardiness Report captured the number of days that the subject was tardy to school, had partial attendance at school or was completely absent from school. Data were collected for the 30-day period prior to Baseline, 6-week period prior to Week 6, 6-week period prior to Week 12.

    Measured: Baseline (Day 0) to Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Mar 2009 (estimated)
  2. Study startMay 2009
  3. Primary completionJul 2011
  4. Study completionJul 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
486 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00856973
Sponsor's protocol ID
190-246
Status last verified
May 2013
First submitted
4 Mar 2009
Last updated
17 Jun 2013
Data monitoring committee
Yes

Publications

  • Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Pediatrics. 2014 Oct;134(4):e1095-103. doi: 10.1542/peds.2013-4221.

    PubMed 25266438

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing eszopiclone in people with Insomnia and Attention Deficit Hyperactivity Disorder, run by Sumitomo Pharma America, Inc. at 73 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 73 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Apr 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS). (time frame: Baseline (Day 0) to Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00856973, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in